Jiangsu Wuzhong Pharmaceutical

Jiangsu Wuzhong Pharmaceutical is a prominent Chinese pharmaceutical company and a core subsidiary of the Shanghai-listed Jiangsu Wuzhong Industrial Co., Ltd. Headquartered in Suzhou, the company integrates R&D, manufacturing, and marketing of a diverse portfolio including anti-infectives, cardiovascular drugs, and gastrointestinal treatments. Recently, the company has undergone a significant strategic transformation to enter the medical aesthetics sector, highlighted by the 2024 China approval of AestheFill, a high-end PDLLA-based injectable filler. Wuzhong Pharma operates multiple GMP-certified production bases and is actively developing a pipeline of recombinant collagen and other innovative aesthetic solutions. The company aims to leverage its established pharmaceutical manufacturing expertise to become a leader in the pharmaceutical and aesthetics dual-core industry in China.